Valor202020212022202320242025TTMGastos comerciales, generales y administrativos1.23 B1.49 B1.57 B1.82 B1.79 B2.09 B2.14 BInvestigación y desarrollo760.7 M903.1 M945.2 M1.07 B1.05 B1.08 B1.09 BBeneficio operativo897.6 M1.69 B1.75 B1.53 B1.38 B1.26 B1.35 BTotal de ingresos no operativos46.8 M34.8 M-13.5 M93.2 M169.4 M8.7 M-49 MGastos por intereses, netos de intereses capitalizados15.8 M18.4 M19.2 M17.6 M19.8 M20.4 M—Ingresos no operativos, una vez deducidos los gastos por intereses19.5 M3.7 M-35.3 M61.2 M100.5 M-18.9 M-125.1 MIngresos/gastos extraordinarios11.5 M12.7 M2.6 M14.4 M68.9 M7.2 M76.1 MBeneficio antes de impuestos916.7 M1.7 B1.77 B1.6 B1.55 B1.27 B1.3 BParticipación en los beneficios———————Impuestos93.3 M198.9 M245.5 M198.7 M152.1 M216.9 M224.9 MParticipación minoritaria———-3 M-4.9 M-4.1 M-2.5 MOtros ingresos/gastos después de impuestos3.5 M23.4 M-7.8 M-8.4 M-18.4 M-7.7 M-4.6 MBeneficio neto antes de actividades interrumpidas823.4 M1.5 B1.52 B1.4 B1.4 B1.06 B1.08 BOperaciones suspendidas————2.77 B13.4 M20.6 MBeneficio neto823.4 M1.5 B1.52 B1.4 B4.17 B1.07 B1.1 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas823.4 M1.5 B1.52 B1.4 B4.17 B1.07 B1.1 BBeneficio básico por acción1.322.412.462.316.981.841.89Beneficio por acción diluido1.32.382.442.36.971.831.88Número medio de acciones ordinarias622.6 M623.3 M619 M606.7 M597.7 M584.8 M—Acciones diluidas631.9 M631.2 M624.2 M609.4 M599.3 M585.8 M—EBITDA1.01 B1.69 B1.85 B1.87 B4.9 B1.21 B1.36 BEBIT905.8 M1.56 B1.71 B1.72 B4.7 B1.05 B1.2 BCosto de los ingresos1.08 B1.25 B1.08 B1.38 B1.12 B1.33 B1.4 BOtros costes de producción00—————Amortización y depreciación (flujo de caja)107.2 M134.8 M139.6 M144.9 M155.2 M156.6 M160.9 M
Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.